# A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

> **NCT04041050** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 85 (actual)

## Conditions studied

- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Navitoclax
- **DRUG:** Ruxolitinib
- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT04041050
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-08
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04041050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04041050, "A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04041050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*